The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Abstract
PURPOSE: A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients. PATIENTS AND METHODS: Newly diagnosed patients were given a daily infusion of CA (100 mg/m2) for 7 days and were assigned randomly to receive DNR (45 mg/m2) or IDR (12 mg/m2) daily for the first 3 days. Those patients who achieved a complete remission (CR) were given three consolidation courses that consisted of CA (100 mg/m2 intravenously [IV]) and thioguanine (TG; 100 mg/m2 orally) every 12 hours for 5 days and either DNR (50 mg/m2) or IDR (15 mg/m2) on the first day of each cycle. After consolidation, patients received late intensification, which consisted of the same drugs used for induction except that the CA was given for 5 days and the anthracycline for 2 days. Four courses were planned at 13-week intervals. RESULTS: The CR rates were 75 of 105 (71%) on the IDR arm and 65 of 113 (58%) on the DNR arm (P = .03). The median survival and median remission durations were 297 and 433 days, respectively, on the IDR arm. The median survival and median remission durations were 277 and 328 days, respectively, on the DNR arm. Six deaths occurred during late intensification, five on IDR and one on DNR; this approach was abandoned after 47 patients were entered. The median survival was significantly longer for patients who received late intensification. CONCLUSION: This trial demonstrated that IDR was more effective than DNR in remission induction in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Covariance Analysis of Censored Survival Data
Breslow, N. (1974) · Biometrics · doi:10.2307/2529620 · Cited by 1,763
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., et al. (1981) · Blood · doi:10.1182/blood.v58.6.1203.1203 · Cited by 532
Wiernik, P., Banks, P., Case, D. J., Arlin, Z., Periman, P., Todd, M., Ritch, P., Enck, R., & Weitberg, A. (1992) · Blood · doi:10.1182/blood.v79.2.313.313 · Cited by 462
Self-citationAcute Promyelocytic Leukemia: Results of Treatment by Daunorubicin
Bernard, J., Weil, M., Boiron, M., Jacquillat, C., Flandrin, G., & Gemon, M.-F. (1973) · Blood · doi:10.1182/blood.v41.4.489.489 · Cited by 338
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia
Cassileth, P. A., Begg, C. B., Bennett, J. M., Bozdech, M. J., Kahn, S., Weiler, C., & Jh, G. (1984) · Blood · doi:10.1182/blood.v63.4.843.843 · Cited by 147
Sauter, C., Fopp, M., Imbach, P. A., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90424-0 · Cited by 117
DAUNORUBICIN IN THE TREATMENT OF ACUTE MYELOCYTIC LEUKÆMIA
Boiron, M., Jacquillat, C., Weil, M., Tanzer, J., Levy, D. E., Sultan, C., & Bernard, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)91296-3 · Cited by 115
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Metadata
- Authors
- Vogler, W. R., Velez-Garcia, E., Weiner, R. S., Flaum, M. A., Bartolucci, A. A., Omura, G. A., Gerber, M. C., & Banks, P. L.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-07
- Volume
- 10
- Issue
- 7
- Pages
- 1103-1111
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1861929829
- Cited by
- 368
- References
- 12
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. https://app.cochat.ai/papers/10.1200/jco.1992.10.7.1103
- The paper
- Vogler, W. R., Velez-Garcia, E., Weiner, R. S., Flaum, M. A., Bartolucci, A. A., Omura, G. A., Gerber, M. C., & Banks, P. L. (1992). A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.7.1103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.